NCT07159022

Brief Summary

During sedated gastroscopy, the insertion of the fiberscope and gastric distension required to perform the examination may induce respiratory depression, airway obstruction, and decreased chest wall compliance. Patients with obesity, especially visceral fat, have poor lung and chest wall compliance, lower lung capacity and functional residual capacity, and an unbalanced ventilation-to-perfusion ratio. Thus, obese patients are at a high risk of hypoxemia. Increasing evidence supports the use of High-flow nasal cannula (HFNC) oxygenation in obese patients during sedated gastrointestinal endoscopy. Obesity, especially visceral obesity, is an established risk factor associated with all-cause mortality. Body roundness index (BRI) is a newer anthropometric measure associated with identification of high-risk individuals. Owing to the limited evidence, we designed this unblinded randomized controlled trial to assess whether HFNC, compared to standard mask oxygenation, improves oxygenation at the end of the procedure (primary endpoint) in patients with visceral obesity.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for not_applicable

Timeline
3mo left

Started Aug 2025

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress75%
Aug 2025Jul 2026

First Submitted

Initial submission to the registry

August 27, 2025

Completed
4 days until next milestone

Study Start

First participant enrolled

August 31, 2025

Completed
8 days until next milestone

First Posted

Study publicly available on registry

September 8, 2025

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2026

Expected
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

July 31, 2026

Last Updated

December 1, 2025

Status Verified

November 1, 2025

Enrollment Period

10 months

First QC Date

August 27, 2025

Last Update Submit

November 27, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Incidence of hypoxia

    SpO2\<90%

    From sedation with propofol to the end of the gastroscopy

Secondary Outcomes (4)

  • Incidence of subclinical respiratory depression

    From sedation with propofol to the end of the gastroscopy

  • Severe hypoxia

    From sedation with propofol to the end of the gastroscopy

  • Serious cardiac events

    Through gastroscopy completion, an average of 10-15 minutes

  • Serious adverse respiratory events

    Through gastroscopy completion, an average of 10-15 minutes

Study Arms (2)

High Flow Nasal Cannula Oxygenation

EXPERIMENTAL

High Flow Nasal cannula is a system to deliver heated and humidified oxygen with an inspired oxygen fraction between 21 and 100% through large bore nasal cannula. The system delivers a flow up to 60 liters/min.

Procedure: High Flow Nasal Cannula Oxygenation

Mask Oxygenation

ACTIVE COMPARATOR

Conventional Oxygenation will be administered through mask

Procedure: Face Mask Oxygenation

Interventions

High Flow Nasal Cannula will be set at 60 liters per minute of air/oxygen admixture to reach a peripheral oxygen saturation equal or greater than 94%

High Flow Nasal Cannula Oxygenation

conventional oxygen therapy will be administered through common mask with a flow up to 6 Liters per minute

Mask Oxygenation

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • ASA class ≤Ⅲ
  • Visceral obesity(body mass index≥28 and BRI ≥5.46)
  • Patients who will undergo sedated gastroscopy

You may not qualify if:

  • Life-threatening heart disease or acute myocardial infarction within 6 weeks
  • Presence of pneumothorax or pulmonary bullae, pulmonary embolism, pulmonary oedema
  • Upper respiratory tract infection
  • Presence of tracheostomy
  • Nasal or nasopharyngeal diseases
  • Coagulation disorders or a tendency of nose bleeding
  • Pregnancy
  • Recent (within 1 week) thoracic surgery
  • Emergent procedure or surgery
  • Allergy to drugs used during the procedure
  • Unwillingness to participate in the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Zhongshan Hospitla

Shanghai, China

RECRUITING

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 27, 2025

First Posted

September 8, 2025

Study Start

August 31, 2025

Primary Completion (Estimated)

June 30, 2026

Study Completion (Estimated)

July 31, 2026

Last Updated

December 1, 2025

Record last verified: 2025-11

Locations